PLOS ONE: Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer

PLOS ONE: Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer

Abstract

"Mutations in RAD51D have been associated with an increased risk of hereditary ovarian cancer and although they have been observed in the context of breast and ovarian cancer families, the association with breast cancer is unclear. The aim of this current study was to validate the reported association of RAD51D with ovarian cancer and assess for an association with breast cancer. We screened for RAD51D mutations in BRCA1/2 mutation-negative index cases from 1,060 familial breast and/or ovarian cancer families (including 741 affected by breast cancer only) and in 245 unselected ovarian cancer cases.......

"...The absence of truncating mutations in 741 breast cancer only families (or 962 breast cancer-affected probands) provides further evidence that RAD51D mutations do not contribute significantly to breast cancer risk."